[Sustained effectiveness of osmotic-release methylphenidate: a study of 266 cases]
A Fernández-Jaén1, D Martín Fernández-Mayoralas, B Calleja-Pérez
1Servicio de Neurología Pediátrica, Hospital de La Zarzuela, Madrid, España. aferjaen@telefonica.net
Introduction:
Methylphenidate (MTF) is effective for the treatment of attention deficit/hiperactivity disorder (ADHD). Osmotic-release MTF (MTF-O) allows a sustained effect along the day on attention and behaviour in patient with ADHD with a single dose.
Aim:
To confirm the sustained effectiveness of the MTF-O from the clinical point of view, in the family circle:
Patients And Methods:
Study of 266 patients with ADHD. They were aged between 5 and 17 years. Distribution for sex 3/1 (boys/girls). Treatment with MTF-O was added and retired in two successive weekends, alternating the days. During these four days the following scales were filled at different hours: quantified criteria of DSM-IV-TR, modified ICG-M, and translated and modified Depremb-R.
Results:
The following finds were observed under treatment: a statistically significant decrease in inattention, hyperactivity and impulsiveness (p < 0.01); a clinical improvement when getting up and going to bed by means of Depremb-R scale (p < 0.01); a reduction of the symptomatic intensity in the criteria of DSM-IV-TR, in the morning and in the afternoon (p < 0.01); a global improvement in attention and behaviour when getting up, lunchtime, dinner, and before going to bed according to the modified ICG-M.
Conclusion:
MTF-O improves characteristic symptoms of ADHD from the first hours of the morning until the hour of going to bed according to family assessment.
Insights
Osmotic-release methylphenidate (MTF-O) effectively manages attention deficit/hyperactivity disorder (ADHD) symptoms. This treatment sustained improvements in attention and behavior throughout the day, as reported by families.
Area of Science:
- Pharmacology
- Neuroscience
- Pediatrics
Context:
- Attention deficit/hyperactivity disorder (ADHD) significantly impacts children's daily functioning.
- Methylphenidate (MTF) is a common pharmacotherapy for ADHD.
- Osmotic-release formulations (MTF-O) aim to provide sustained symptom control.
Purpose:
- To evaluate the sustained effectiveness of osmotic-release methylphenidate (MTF-O) in pediatric ADHD patients.
- To assess MTF-O's impact on attention, hyperactivity, and impulsivity within a family context.
Summary:
- A study involving 266 ADHD patients (ages 5-17) assessed MTF-O treatment over four days, alternating between on and off treatment weekends.
- Validated scales (DSM-IV-TR, ICG-M, Depremb-R) were used to quantify symptom changes.
- Results showed statistically significant reductions in inattention, hyperactivity, and impulsivity (p < 0.01) with MTF-O.
Impact:
- MTF-O demonstrated sustained clinical improvement in ADHD symptoms from morning to bedtime, according to family-reported outcomes.
- The findings support MTF-O as an effective treatment for improving attention and behavior in children with ADHD throughout the day.
More Related Videos
11:17Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
Published on: November 25, 2025
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
01:23Ophthalmic Drug Delivery Systems
01:23Modified-Release Drug Delivery Systems: Classification
01:20Modified-Release Drug Delivery Systems: Influencing Factors
01:19Modified-Release Drug Delivery Systems: Overview
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics